Physician profile
Lisa Mcmath
NPI 1407819204
$911.54
in general payments reported to CMS, 2019-2025
17 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $167 · 2021: $70.39 · 2024: $244 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $146.78 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $142.49 | 2024-2025 | Azstarys, Azstarys |
| Glaxosmithkline, LLC. | $137.11 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $105.03 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $85.81 | 2020-2025 | Trintellix |
| Neos Therapeutics, LP | $66.71 | 2020-2025 | Adzenys Xr-Odt, Exxua |
| Vanda Pharmaceuticals INC. | $33.90 | 2025 | Fanapt |
| Kaleo, INC. | $33.15 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $23.08 | 2019-2021 | |
| Noven Therapeutics, LLC | $21.26 | 2024 | Xelstrym |
| Janssen Pharmaceuticals, INC | $20.01 | 2025 | Spravato |
| Pfizer INC. | $18.13 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.00 | 2021 | |
| Shire North American Group INC | $16.09 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.85 | 2025 | Jornay Pm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.79 | 2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $14.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Mcmath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.